NRG Oncology Biospecimen Bank Report NRG Semiannual meeting General Session Richard Jordan DDS PhD FRCPath Nilsa Ramirez, MD Peter Lucas, MD, PhD Jeffry Simko, MD, PhD NRG Semiannual meeting Phoenix February 2019

NRG Oncology Open Trials Open Trials on January 20, 2019 Disease Site # Trials Target Accrual Accrued Cases GU 4 4,407 2,791 Breast 5 5,786 2,384 GYN 11 3,669 2,090 H&N 1,721 752 Brain 972 670 GI 1,023 466 Lung 870 350 Sarcoma 1 46 Totals 37 18,494 9,503

NRGBB Inventory NRGBB Year 4 TOTALS Total Cases (Patients) with Biospecimens 233,376 Total Biospecimens 2,733,234 Total Cases (Patients) Received Years 1-4 12,217 Total Biospecimens Received Years 1-4 230,468 Total Biospecimens Distributed Years 1-4 78,761

NRGBB Years 1-4 (2015-2018) Biospecimen Distributions by Organ Site Disease Site # Trials # Specimens # Patients GYN 22 41,948 3,982 Breast 5 14,076 10,564 Brain 10 7,839 1,685 GU 8 7,752 1,024 GI 4 4,189 520 H&N 7 2,957 970   TOTALS for NRG 56 78,761 18,745

Data uploaded into NCI-Navigator January 2019 Lead Group Trials Specimens NRG-O 47 474,655 Alliance 30 149,388 SWOG 17 80,202 ECOG-ACRIN 16 46,204 TOTAL 110 750,449

four Cancer Immune Monitoring and Analysis Centers (CIMACs) Dana-Farber Cancer Institute, Stanford University, MD Anderson, and Mount Sinai,  analyses for genomic, phenotypic and functional characterization of responses of patients in early phase clinical trials

CIMAC Trials and NRG Oncology $600K U24 Supplement for Year 4 awarded to NRG in October. Ends March 31 2019. Supplement for extra costs related to Navigator, special tubes, other studies/costs not funded by original U24 RFA. NRGBB agreed to change priority of funding to CIMAC costs first NCE will be requested as needed. ONE trial is now active- LU004. 3 concepts being discussed.